AstraZeneca to Build Radioligand Therapy Manufacturing Hub in Guangzhou – Actinium‑225 Facility Targets Asia‑Pacific Cancer Market
AstraZeneca PLC (NASDAQ: AZN) has signed a Memorandum of Understanding with the Guangzhou Economic and...
AstraZeneca
AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer – Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial
AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with...
FDA Accepts ENHERTU sBLA with Priority Review – HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction
AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has...
AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences
AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase...
Keymed Biosciences Initiates CMG901 Phase III – AstraZeneca Triggers $45 Million Milestone for Claudin 18.2 ADC
Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901,...
AstraZeneca China Reorganizes Biopharma Operations – Omni-Channel Unit and Early Oncology Pipeline Restructuring
AstraZeneca Plc’s (AZ, NASDAQ: AZN) China unit announced a strategic reorganization of its biopharmaceutical operations,...
FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen
AstraZeneca (AZ, NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved the...
AstraZeneca Reports 8% Revenue Growth to $58.7 Billion in 2025; Oncology Leads with 17% Surge
AstraZeneca PLC (AZ, NASDAQ: AZN) delivered strong 2025 financial results, with total revenues rising 8% year-on-year...
AstraZeneca Saphnelo Faces FDA Setback with Complete Response Letter
AstraZeneca (AZ, NASDAQ: AZN) announced it has received a Complete Response Letter (CRL) from the U.S....
Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer
AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration...
Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation
AstraZeneca (AZ, NASDAQ: AZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has...
AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
AstraZeneca (AZ, NASDAQ: AZN) announced a plan to invest RMB 100 billion (USD 14.4 billion) :in China by 2030 to...
AstraZeneca’s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis
AstraZeneca plc (AZ, NASDAQ: AZN) announced that China’s National Medical Products Administration (NMPA) has approved Soliris...
Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets
Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China‑based joint venture established by AstraZeneca (AZ, NASDAQ: AZN)...
Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
AstraZeneca plc (AZ, NASDAQ: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan)...
AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication
AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) has been officially approved in China for use...
AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification
AstraZeneca plc (AZ, NASDAQ: AZN) announced it will delist its American Depositary Shares (ADS) and debt...
AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal
AbelZeta Pharma, Inc. (Sino‑US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ: AZN) granting AZ the...
AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
AstraZeneca plc (AZ, NASDAQ: AZN) announced the acquisition of Modella AI, a leader in artificial intelligence...